CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B

Name: CRISPR-Cas-Based Genome Editing for Treating Human Diseases - Part B
Brand: Elsevier Science Publishing Co Inc
Price: 500.25 AUD
Availability: PreOrder

Volume 210

By: Vijai Singh (Editor)

Write A Review

Hardcover | 1 January 2025

At a Glance

Hardcover
300 Pages

Dimensions(cm)
22.86 x 15.24

Hardcover

$500.25

or 4 interest-free payments of $125.06 with

or

Available: 1st January 2025

Preorder. Will ship when available.

CRISPR-Cas-Based Genome Editing for Treating Human Diseases, Part B represents CRISPR-Cas systems for genome editing. Currently, CRISPR-Cas systems have been proven to be a key technology for targeted genome editing, which is acting as a simple, rapid, and cost-effective solution. Chapters in this release include Current approaches in CRISPR -Cas systems for metabolic disorders, Recent progress in CRISPR -Cas systems for CRISPR for retinal diseases, Recent progress in CRISPR -Cas systems for cataract and blindness, Advances in CRISPR -Cas systems for muscular dystrophy, Recent development in CRISPR -Cas systems for cardiac disease, Current approaches in CRISPR -Cas systems for diabetes, and much more.

Additional sections cover Advances in CRISPR -Cas systems for liver disease, Advances in CRISPR -Cas systems for lung disease, Advances in CRISPR -Cas systems for kidney diseases, Current progress in CRISPR -Cas systems for rare disease, Advances in CRISPR -Cas systems for heredity disease, Recent progress in CRISPR -Cas systems for neurological disorders, and CRISPR challenges in clinical developments.

Shipping

	Standard Shipping	Express Shipping
Metro postcodes:	$9.99	$14.95
Regional postcodes:	$9.99	$14.95
Rural postcodes:	$9.99	$14.95

How to return your order

At Booktopia, we offer hassle-free returns in accordance with our returns policy. If you wish to return an item, please get in touch with Booktopia Customer Care.

Additional postage charges may be applicable.